Negative impactResults
Glenmark Pharma Q2 Results: Net profit plunges 56% to Rs 264 crore, revenue down at Rs 4,247 cr
Economic Times 1 hr ago·5 Nov 2026, 2:38 pm
Glenmark Pharmaceuticals experienced a 56.78 percent drop in consolidated profit after tax during the September quarter. Total revenue from operations decreased to Rs 4,247.32 crore compared to the previous year. The company's total expenses also decreased during the same period, indicating some operational efficiency. A subsidiary of Glenmark Pharma entered into a settlement for USD 15 million with Humana Inc.
Affected stocks
Bearish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Glenmark Pharmaceuticals (GLENMARK).
- Category: Results.
- AI reads the tone as negative (potentially bearish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Glenmark Pharmaceuticals worth tracking. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
